Ispire Technology Q2 Earnings Call Highlights

1 month ago 23

MarketBeat

Fri, February 6, 2026 astatine 9:10 AM CST 7 min read

Ispire Technology logo

Ispire’s gross fell to $20.3 million from $41.8 million year-over-year arsenic absorption intentionally realigned distant from lower-value cannabis customers toward higher-quality nicotine clients, accepting near-term top-line declines to amended outgo profiles.
Cost cuts and tighter collections lowered operating expenses to $10.3 million and narrowed nett nonaccomplishment to $6.6 million, with accounts receivable improving to $37.9 million, currency collected versus gross astatine 116%, and operating currency pain of astir $1 million from April–Dec 2025.
Strategic maturation drivers see the IKE Tech age-gating JV—seeing intensified involvement from large baccy companies and an upcoming “significant” deal—and product/production initiatives similar G-Mesh hardware and a Malaysia build-out that could grow capableness from 6 to 80 accumulation lines (with archetypal spot volumes for a spouse targeting 2–3M per month, up to 10M).
Interested successful Ispire Technology Inc.? Here are 5 stocks we similar better.

Ispire Technology (NASDAQ:ISPR) executives told investors the company’s fiscal 2nd 4th marked an “inflection point” pursuing a twelvemonth of cost-cutting and a strategical displacement toward higher-quality nicotine customers, adjacent arsenic gross fell sharply twelvemonth implicit year.

On the company’s net telephone covering the 4th ended December 31, 2025, Co-CEO Michael Wang and CFO Jay Yu said Ispire’s deliberate lawsuit and product-mix realignment reduced income successful the play but improved respective measures tied to currency collection, operating expenses, and nett loss. Management besides highlighted ongoing enactment connected its IKE Tech age-gating associated venture, G-Mesh hardware technology, and enlargement of manufacturing capableness successful Malaysia.

→ AMD’s Post-Earnings Dip Looks Like the Buying Window Bulls Wanted

Yu said Ispire reported full gross of $20.3 million for the fiscal 2nd quarter, down from $41.8 million successful the prior-year quarter. Management attributed the diminution to a strategical “realignment” distant from a lower-value cannabis lawsuit basal and toward nicotine-sector customers with “better outgo profiles.”

Wang characterized the gross diminution arsenic expected, saying the institution had consolidated its lawsuit basal since precocious fiscal 2025 to prioritize “high-quality clients” and determination distant from slower-paying customers. He besides noted headwinds successful the planetary nicotine sector, including declining e-cigarette measurement and pricing unit from Chinese manufacturers, portion arguing that rising costs successful China could yet payment Malaysian producers—an country wherever Ispire is focusing production.